The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000329.3(RPE65):c.65T>C (p.Leu22Pro)

CA226576

98888 (ClinVar)

Gene: RPE65
Condition: RPE65-related recessive retinopathy
Inheritance Mode: Autosomal recessive inheritance
UUID: c08da84b-5627-46e5-af56-e4e3c3ee7130
Approved on: 2024-02-18
Published on: 2024-02-18

HGVS expressions

NM_000329.3:c.65T>C
NM_000329.3(RPE65):c.65T>C (p.Leu22Pro)
NC_000001.11:g.68448653A>G
CM000663.2:g.68448653A>G
NC_000001.10:g.68914336A>G
CM000663.1:g.68914336A>G
NC_000001.9:g.68686924A>G
NG_008472.1:g.6307T>C
NG_008472.2:g.6307T>C
ENST00000262340.6:c.65T>C
ENST00000262340.5:c.65T>C
NM_000329.2:c.65T>C

Likely Pathogenic

Met criteria codes 5
PS3_Supporting PP3 PM3 PP4_Moderate PM2_Supporting
Not Met criteria codes 2
BA1 BS1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Leber Congenital Amaurosis/early onset Retinal Dystrophy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RPE65 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Leber Congenital Amaurosis/early onset Retinal Dystrophy VCEP
NM_000329.3(RPE65):c.65T>C is a missense variant causing substitution of leucine with proline at position 22. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00002137, with 2 alleles / 16214 total alleles in the African/African-American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). At least one proband harboring this variant exhibits a phenotype including onset in infancy (1 pt), nyctalopia since childhood (0.5 pts), diagnosis based on a 300-gene testing panel that did not provide an alternative explanation for visual impairment (2 pts), non-detectable rod ERG response (0.5 pts), reduced cone ERG response (1 pt), reduced visual acuity (1 pt), light-seeking behavior (1 pt), retinal vessel attenuation (0.5 pts), optic nerve pallor (0.5 pts), and pigment clumping (0.5 pts), which together are highly specific for RPE65-related recessive retinopathy (8 total points, VCEP member-provided data, PP4_Moderate). This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was homozygous for the variant (0.5 pts, PMID: 35129589, PMID: 28127548, VCEP member-provided data). This variant has also been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with the NM_000329.3(RPE65):c.1067dup (p.Asn356fs) or NM_000329.3(RPE65):c.10C>T (p.Gln4Ter) variants suspected in trans (1 pt, PMID: 35129589), which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP (1.5 total pts, PM3). The computational predictor REVEL gives a score of 0.711, which is above the ClinGen LCA / eoRD VCEP PP3 threshold of ≥0.644 and predicts a damaging effect on RPE65 function (PP3). The variant exhibited 2.8-13.5% enzymatic activity in retinoid isomerase assays relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 18599565, PMID: 24849605, PMID: 26427455). In summary, this variant meets the criteria to be classified as likely pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PS3_Supporting, PM2_Supporting, PM3, PP3, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).
Met criteria codes
PS3_Supporting
The variant exhibited 2.8-13.5 % enzymatic activity in retinoid isomerase assays relative to the wild-type control, which is lower than the ClinGen LCA / eoRD PS3_Supporting threshold of <10% activity, indicating that it triggers a severe defect in protein function (PS3_Supporting, PMID: 18599565, PMID: 24849605, PMID: 26427455).
PP3
The computational predictor REVEL gives a score of 0.711, which is above the ClinGen LCA/eoRD VCEP PP3 threshold of ≥0.644 and predicts a damaging effect on RPE65 function (PP3). The splicing impact predictor SpliceAI gives a score of 0.00, which is below the ClinGen LCA / eoRD VCEP recommended threshold of ≥0.2 and does not strongly predict an impact on splicing.
PM3
This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was homozygous for the variant (0.5 pts, PMID: 35129589, PMID: 28127548, VCEP member-provided data). This variant has also been reported in at least 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with the NM_000329.3(RPE65):c.1067dup (p.Asn356fs) or NM_000329.3(RPE65):c.10C>T (p.Gln4Ter) variants suspected in trans (1 pt, PMID: 35129589), which were previously classified pathogenic by the ClinGen LCA / eoRD VCEP (1.5 total pts, PM3). The variant is confirmed in trans with the NM_000329.3(RPE65):c.208T>G (p.Phe70Val) variant (PMID: 17724218) and NM_000329.3:c.201_202delinsTT (p.His68Tyr) variant (PMID: 9801879, PMID: 11264131) and suspected in trans with the NM_000329.3(RPE65):c.272G>C (p.Arg91Pro) variant, but these have not been considered for PM3 in order to avoid the possibility of circularity.
PP4_Moderate
At least one proband harboring this variant exhibits a phenotype including onset in infancy (1 pt), nyctalopia since childhood (0.5 pts), diagnosis based on a 300-gene testing panel that did not provide an alternative explanation for visual impairment (2 pts), non-detectable rod ERG response (0.5 pts), reduced cone ERG response (1 pt), reduced visual acuity (1 pt), light-seeking behavior (1 pt), retinal vessel attenuation (0.5 pts) optic nerve pallor (0.5 pts), and pigment clumping (0.5 pts), which together are highly specific for RPE65-related recessive retinopathy (8 total points, VCEP member-provided data, PP4_Moderate).
PM2_Supporting
This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.00002137, with 2 alleles / 16214 total alleles in the African/African-American population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting).
Not Met criteria codes
BA1
The Popmax Filtering AF for this variant in gnomAD v.2.1.1 is 0.00002137. This allele frequency is lower than the ClinGen LCA/eoRD VCEP threshold (>0.00816) for this criterion.
BS1
The Popmax Filtering AF for this variant in gnomAD v.2.1.1 is 0.00002137. This allele frequency is lower than the ClinGen LCA/eoRD VCEP threshold (>0.000816) for this criterion.
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.